生物流程市場與預測，2023年

生物過程利用細胞、細胞成分、病毒和整個生物體等生物系統來生產商業產品。此過程由兩個主要階段組成：上游生物過程和下游生物過程。在上游過程中，所需的細胞係被分離、培養並放大至最終產物所需的量。然後使用生物反應器收穫細胞，生物反應器可以是一次性的，也可以是常規的，這取決於生物體的複雜性和數量。下游加工是生產的後期階段，上游加工結束時收穫的細胞和其他生物體經過純化，以產生符合嚴格安全和品質標準的最終產品。此階段通常採用過濾、濃縮和色譜等技術。

生物製劑是由活細胞產生的高度複雜的治療分子，預計在未來五年內將顯著超過小分子銷售額。生物製品包括多種產品，包括疫苗、血液成分、基因治療藥物、重組治療蛋白和白血球介素。這種轉變是由生物製劑批准的增加以及對製造更複雜的藥物分子（例如單株抗體（mAb））的關注所推動的。此外，為了解決專利聚合物療法的高成本問題，對生物相似藥的需求正在增加，預計未來五年將出現爆炸性增長。

COVID-19 大流行加快了開發時間，在某些情況下，從最初發現到研究藥物批准的過程縮短至3-6 個月，中和單株抗體在14 個月內獲得緊急使用授權。它也很快在世界各地以數千公斤的量批量生產用於治療目的。這些成就凸顯了該領域令人印象深刻的技術進步。生物製劑開發取得的前所未有的速度改變了整個產業，並為進一步增強技術鋪平了道路，以降低製造成本，同時滿足不斷增長的需求。未來的成長預計將由採用連續流程、一次性系統以及與人工智慧工具相結合的先進數位化和自動化的新型小型設施來推動。從長遠來看，這些創新預計將塑造該產業的發展軌跡。

本報告提供生物流程市場相關調查，彙整各產品類型，各地區的趨勢，參與企業相關等資訊。

目錄

• 傳統的生物反應器
• 單回使用·生物反應器
• 細胞培養培養基和補充品
• 過濾與濃縮
• 流程層析法
• 實驗室設備
• 最近的事業活動與市場開拓
  • 3M
  • Agilent
  • Applikon Biotechnology
  • AsahiKASEI
  • Astrea Bioseparations
  • Avantor
  • Bio-Rad
  • Corning
  • Cytiva
  • Daicel/Chiral Technologies
  • Daiso
  • Eppendorf
  • Infors HT
  • MilliporeSigma (Merck)
  • Phenomenex
  • Pierre Guerin
  • Repligen
  • Sartorius
  • Thermo Fisher
  • Tosoh
  • WR Grace

BIOPROCESSING INSTRUMENTATION MARKET ANALYSIS

Bioprocessing involves utilizing biological systems, such as cells, cell components, viruses, or entire organisms to produce commercial products. This process consists of two main stages: upstream bioprocessing and downstream bioprocessing. In the upstream segment, the target cell line is isolated, cultured, and scaled up to the desired volume for the final product. The cells are then harvested using bioreactors, which can be either single-use or conventional, depending on the complexity and volume of the organism. The downstream segment involves the later stages of production and involves purifying cells or other organisms collected at the end of the upstream stage to create a final product that meets stringent safety and quality standards. Techniques such as filtration, concentration and chromatography are commonly employed at this stage.

Biologics, the highly complex therapeutic molecules produced by living cells, are expected to significantly overtake small molecules sales over the next five years. Biologics encompass a wide range of products, including vaccines, blood components, gene therapies, recombinant therapeutic proteins, interleukins and more. This shift is driven by the increasing approval of biologics and a focus on manufacturing more intricate drug molecules such as monoclonal antibodies (mAb). Additionally, there is a growing demand for biosimilars to address the high cost of patented large molecule therapies, which are poised to witness explosive growth over the next five years.

The COVID-19 pandemic expedited development timelines, with initial discovery to investigational new drug processes shortened to 3-6 months in some cases, and neutralizing mAbs obtained emergency use authorization within 14 months. Large-scale manufacturing of thousands of kilograms for therapeutic purposes worldwide quickly followed. These achievements highlight the remarkable technological advances in the field. The unprecedented speed achieved in biologics development has transformed the industry and paved the way for further enhancements in reducing manufacturing costs while meeting rising demands. Future growth will be fueled by the adoption of new, smaller facilities that employ continuous processes, single-use systems and sophisticated digitalization and automation coupled with AI tools. These innovations are expected to shape the industry's trajectory in the long term.

SDi's “2023 Bioprocess Instrumentation Market ” observes the market dynamics and specific trends influencing the industry and analyzes their effect on sales growth for instruments and other products employed in bioprocessing. As the leading provider of market research on analytical instrumentation, SDi has crafted this report to evaluate and explain what is currently driving this important market. The bioprocessing instrument market in this report includes bioreactors, cell culture media & supplements, and chromatography. These instruments are categorized into six different technologies that represent the overall market covered in this report.

Report Overview:

Market demand segmented by product type and region along with yearly market forecasts through 2027. The market estimates have been newly updated with 2022 as the base year and estimates are provided for the following techniques:

• 1. Conventional Bioreactors
• 2. Single-Use Bioreactors
• 3. Cell Culture Media & Supplements
• 4. Filtration & Concentration
• 5. Process Chromatography
• 6. Lab Equipment

Summary of recent market developments and dynamics that are shaping our view of the market, including recent business activities.

Vendor share for participating suppliers in each technology category employed by the bioprocessing industry. Some of the top vendors in the overall market are presented below, in alphabetical order: